M. Beumont‐Mauviel

发表

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.

Thomas Berg, Stefan Zeuzem, Oliver Lenz, 2014, Gastroenterology.

9 TMC435 IN PATIENTS INFECTED WITH HCV GENOTYPE 1 WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: VIROLOGIC ANALYSES OF THE ASPIRE TRIAL

S. Zeuzem, M. Peeters, O. Lenz, 2012 .

In vitro inactivation of Chlamydia trachomatis and of a panel of DNA (HSV-2, CMV, adenovirus, BK virus) and RNA (RSV, enterovirus) viruses by the spermicide benzalkonium chloride.

L. Bélec, J. Malkin, M. Beumont‐Mauviel, 2000, The Journal of antimicrobial chemotherapy.

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir

S. Ouwerkerk-Mahadevan, J. Snoeys, M. Peeters, 2015, Clinical Pharmacokinetics.

svr results of a once-daily regimen of simeprevir (tmc435) plus sofosbuvir (gs-7977) with or without ribavirin in cirrhotic and non-cirrhotic Hcv genotype 1 treatment-naïve and prior null responder patients: The Cosmos study : lb-3

Brian L. Pearlman, Z. Younossi, S. Ouwerkerk-Mahadevan, 2013 .

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies

X. Forns, S. Zeuzem, S. Ouwerkerk-Mahadevan, 2015, Journal of viral hepatitis.

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

M. Manns, M. Buti, P. Marcellin, 2014, The Lancet.

Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.

X. Forns, S. Zeuzem, A. Horban, 2014, Gastroenterology.

Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: The randomized PILLAR study

M. Manns, M. Buti, M. Sherman, 2013, Hepatology.

869a Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype-1 Infection in Treatment-Naive Patients: Results From QUEST-2, a Phase III Trial

M. Manns, M. Buti, P. Marcellin, 2013 .

1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL

M. Manns, M. Buti, P. Marcellin, 2013 .

O165 SIMEPREVIR PLUS SOFOSBUVIR WITH/WITHOUT RIBAVIRIN IN HCV GENOTYPE 1 PRIOR NULL-RESPONDER/TREATMENT-NAIVE PATIENTS (COSMOS STUDY): PRIMARY ENDPOINT (SVR12) RESULTS IN PATIENTS WITH METAVIR F3–4 (COHORT 2)

Brian L. Pearlman, Z. Younossi, S. Ouwerkerk-Mahadevan, 2014 .

A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

V. Miller, F. Zoulim, M. Yuen, 2022, Nature reviews: Gastroenterology & hepatology.

Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications

S. Khoo, D. Back, S. Ouwerkerk-Mahadevan, 2018, British journal of clinical pharmacology.

A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

V. Miller, F. Zoulim, M. Yuen, 2022, Nature Reviews Gastroenterology & Hepatology.

Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor.

B. Samuelsson, M. Cummings, Magnus Nilsson, 2014, Journal of medicinal chemistry.

Virological analysis of patients receiving Telaprevir administered Q8H or Q12H with Peginterferon-Alfa-2A or -Alfa-2B and Ribavirin in treatment-naive patients with Genotype I hepatitis C: study C208

P. Marcellin, X. Forns, F. Nevens, 2009 .

10 RESULTS OF A PROOF OF CONCEPT STUDY (C210) OF TELAPREVIR MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 4 HCV PATIENTS

V. Ratziu, J. Moussalli, P. Lebray, 2009 .

50 ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: INTERIM RESULTS OF STUDY C209

O. Weiland, G. Foster, G. Carosi, 2009 .

Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment

S. Ouwerkerk-Mahadevan, G. Mannens, M. Peeters, 2015, Drugs in R&D.

Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference

M. Buti, V. Miller, A. Lok, 2019, Hepatology.

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Oliver Lenz, G. Dore, G. Foster, 2014, The Lancet.

Subanalyses of the Telaprevir Lead-in ARM in the Realize Study: Response at Week 4 is Not a Substitute for Prior Null Response Categorization

S. Zeuzem, S. Pol, Z. Younossi, 2011 .

Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data

M. Buti, M. Biermer, T. Asselah, 2020, Journal of Hepatology.

Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.

Ronald Pruitt, Stefan Zeuzem, Dominique Thabut, 2016, Journal of hepatology.

Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients

C. Rouzioux, Y. Lévy, J. Guillet, 2005, AIDS.

869b Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-Based Therapy: Results From PROMISE, a Phase III Trial

X. Forns, S. Zeuzem, A. Horban, 2013 .

Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study.

C. Rouzioux, Y. Lévy, R. El Habib, 2007, AIDS research and human retroviruses.

J. Aerssens, S. Zeuzem, S. Pol, 2011 .

Efficacy and safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: results from REEF-2 study

M. Buti, M. Biermer, P. Lampertico, 2022, Journal of Hepatology.

P221 VIROLOGY ANALYSES OF SIMEPREVIR IN PHASE 2B AND 3 STUDIES

M. Peeters, O. Lenz, M. Beumont‐Mauviel, 2014 .

Sa2072 Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial

G. Dore, G. Foster, S. Ouwerkerk-Mahadevan, 2013 .

PostersLate-Breaker Poster Abstracts1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL

G. Dore, G. Foster, S. Ouwerkerk-Mahadevan, 2013 .

Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen supression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment

M. Biermer, Wei Cheng, R. Gish, 2020, Journal of Hepatology.

Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.

Cameron K. Murray, Glenda F. Brown, Patrick B. Dorr, 2023, JAMA.

943f TMC435 in HCV Genotype 1 Patients Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Final SVR24 Results of The ASPIRE Trial

T. Berg, S. Zeuzem, G. Hirschfield, 2012 .

2 TMC435 IN HCV GENOTYPE 1 PATIENTS WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: FINAL SVR24 RESULTS OF THE ASPIRE TRIAL

T. Berg, S. Zeuzem, G. Hirschfield, 2012 .

Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.

X. Forns, S. Zeuzem, A. Horban, 2014, Gastroenterology.

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.

S. Zeuzem, G. Hirschfield, P. Ferenci, 2014, Gastroenterology.

Once-Daily Simeprevir (TMC435) With Pegylated Interferon and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C: The Randomized PILLAR Study

M. Buti, P. Marcellin, R. Flisiak, 2014 .